Actively Recruiting

Phase 4
Age: 18Years +
All Genders
NCT07268222

Metyrapone Versus Osilodrostat in Patients With Metabolic Autonomous Cortisol Secretion (MACS)

Led by Laikο General Hospital, Athens · Updated on 2025-12-05

150

Participants Needed

1

Research Sites

103 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study will compare the efficacy and safety of the two 11β-hydroxylase inhibitors-metyrapone and osilodrostat-in patients with MACS. Primary outcome To compare the efficacy (biochemical and clinical) of the two 11β-hydroxylase inhibitors (CYP11B1), metyrapone and osilodrostat, in patients with MACS not treated surgically (mainly bilateral adenomas or adrenal hyperplasias), as well as their side effects at time 0-, 3- and 6-months post-treatment. Secondary outcome To evaluate alterations in clinical parameters (Blood Pressure, Body Mass Index-BMI), metabolic parameters (fasting blood glucose, insulin, Hb1Ac, HOMA, OGTT and lipids levels) at time 0-, 3- and 6-month after the initiation of the treatment and their effect on Bone Mineral Density (BMD) 1 year post-diagnosis

CONDITIONS

Official Title

Metyrapone Versus Osilodrostat in Patients With Metabolic Autonomous Cortisol Secretion (MACS)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults over 18 years old with MACS and unilateral or bilateral adrenal adenomas or hyperplasia confirmed by imaging
  • Cortisol levels greater than 1.8 bcg/dl at 8:00 am after a 1 mg overnight dexamethasone suppression test
  • One of the following: ACTH below 15 pg/ml, abnormal midnight salivary cortisol, or urinary free cortisol levels above the upper normal limit in 24 hours
Not Eligible

You will not qualify if you...

  • Abnormal liver enzymes
  • Kidney function (eGFR) less than 40 ml/min/1.73 m2
  • Pseudocushing syndrome
  • Any history of malignancy, including adrenocortical carcinoma
  • ACTH-dependent Cushing syndrome, including Cushing disease or ectopic Cushing syndrome

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Laikon General Hospital

Athens, Greece

Actively Recruiting

Loading map...

Research Team

A

Anna Angelousi, MD, PhD, Msc

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Metyrapone Versus Osilodrostat in Patients With Metabolic Autonomous Cortisol Secretion (MACS) | DecenTrialz